Harpoon Therapeutics EBITDA vs. Revenue

HARPDelisted Stock  USD 0.85  0.00  0.00%   
Based on Harpoon Therapeutics' profitability indicators, Harpoon Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Harpoon Therapeutics' ability to earn profits and add value for shareholders.
For Harpoon Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Harpoon Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Harpoon Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Harpoon Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Harpoon Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Please note, there is a significant difference between Harpoon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Harpoon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harpoon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Harpoon Therapeutics Revenue vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Harpoon Therapeutics's current stock value. Our valuation model uses many indicators to compare Harpoon Therapeutics value to that of its competitors to determine the firm's financial worth.
Harpoon Therapeutics is one of the top stocks in ebitda category among its peers. It is rated # 3 in revenue category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Harpoon Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Harpoon Revenue vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Harpoon Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(35.45 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Harpoon Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
37.34 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Harpoon Revenue vs Competition

Harpoon Therapeutics is rated # 3 in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 216.2 Million. Harpoon Therapeutics retains roughly 37.34 Million in revenue claiming about 17% of equities under Health Care industry.

Harpoon Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Harpoon Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Harpoon Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Harpoon Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Harpoon Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the bodys immune system to treat patients suffering from cancer and other diseases in the United States. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Harpoon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 95 people.

Harpoon Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Harpoon Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Harpoon Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Harpoon Therapeutics' important profitability drivers and their relationship over time.

Use Harpoon Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Harpoon Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Harpoon Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Harpoon Therapeutics Pair Trading

Harpoon Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Harpoon Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Harpoon Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Harpoon Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Harpoon Therapeutics to buy it.
The correlation of Harpoon Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Harpoon Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Harpoon Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Harpoon Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Harpoon Therapeutics position

In addition to having Harpoon Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Asset Allocation ETFs Thematic Idea Now

Asset Allocation ETFs
Asset Allocation ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Asset Allocation ETFs theme has 146 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Allocation ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Consideration for investing in Harpoon Stock

If you are still planning to invest in Harpoon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Harpoon Therapeutics' history and understand the potential risks before investing.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges